Utah Life Sciences Companies Talk Innovation and Investment with United Arab Emirates Delegation

December 7, 2018

On December 6, Recursion and World Trade Center Utah, in conjunction with BioUtah, hosted a meeting with representatives from the United Arab Emirates (UAE), who were in Utah to explore potential investment and partnership opportunities, including in the life sciences. The meeting was held at Recursion’s new headquarters. Representing the UAE were Saud Al Nowais, UAE Minister Counselor for Trade and Investment, and Jonathan Garon, Director of Commercial Affairs.

Miles Hansen, President and CEO of World Trade Center Utah, Kevin Lynch, Chief Business Officer at Recursion and Kelvyn Culimore, BioUtah President and CEO, opened the discussion. A number of Utah life sciences companies were on hand to showcase their work and highlight Utah’s fast-growing medical technology, diagnostic and drug discovery sectors. In addition to Recursion, in which the UAE sovereign fund has invested, companies attending the meeting – largely early stage – included A6, ApolloDx/CibusDx, Church and State (as a business incubator), Clene Nanomedicine, Lineagen, Navigen, and Signpath Pharma.

Pictured in the photo from left to right.

Craig Mosman (ApolloDx/CibusDx), Meg Garfield (WTC), Jonathan Garon (UAE), Miles Hansen (WTC), Saud Al Nowais (UAE), Kevin Lynch (Recursion), Andy Robertson (ProLung), and Rodney Rassmusen (Signpath Pharma)